AAREYDRUGS — Aarey Drugs and Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- IN₹1.32bn
- IN₹1.62bn
- IN₹4.19bn
- 49
- 58
- 52
- 54
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,547 | 3,001 | 3,484 | 4,927 | 4,190 |
Cost of Revenue | |||||
Gross Profit | 138 | 99.1 | 106 | 206 | 151 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,479 | 2,978 | 3,447 | 4,834 | 4,124 |
Operating Profit | 68.8 | 23.4 | 37.2 | 92.8 | 66 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 89.9 | 72.4 | 83 | 100 | 60.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 65.4 | 57.9 | 65.1 | 65.4 | 37.7 |
Net Income Before Extraordinary Items | |||||
Net Income | 65.4 | 57.9 | 65.1 | 65.4 | 37.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 65.4 | 57.9 | 65.1 | 65.4 | 37.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.8 | 2.48 | 2.79 | 2.72 | 1.5 |